Abemaciclib is a kinase inhibitor of cyclin-dependent kinases 4 and 6 (CDK4 and CDK6). By blocking these kinases, it inhibits retinoblastoma protein phosphorylation and blocks progression from G1 into S phase of the cell cycle. It is studied in breast neoplasms, including hormone receptor-positive, HER2-negative breast cancer.
Summary written with AI from the sources listed at the end of this page.
HR-positive, HER2-negative early breast cancer at high risk of recurrence (adjuvant, with tamoxifen or an aromatase inhibitor)
HR-positive, HER2-negative advanced or metastatic breast cancer (with an aromatase inhibitor as initial endocrine-based therapy)
HR-positive, HER2-negative advanced or metastatic breast cancer (with fulvestrant after progression on endocrine therapy)
HR-positive, HER2-negative advanced or metastatic breast cancer (monotherapy after endocrine therapy and prior chemotherapy in the metastatic setting)
From the indications section of the FDA label (version of Jul 13, 2026). Read the full label for the exact wording, limitations and safety information.
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.